You are here: Industry Insights > antibiotic

News List

Everything You Need to Know About Ceftiofur and Where to Buy in Bulk Quantities PharmaSources
May 17, 2021
Ceftiofur is a broad-spectrum cephalosporin antibiotic with a significant action on gram-positive and gram-negative bacteria, such as beta-lactamase-producing strains.
The key to a powerful antibiotic's formation now clear WorldPharmaNews
February 07, 2022
A powerful class of antibiotics called carbapenems can circumvent antibiotic resistance thanks to a particular chain of atoms in their structure. Now, a team of researchers from Penn State and Johns Hopkins University...
Press Release New resistance-busting antibiotic combination could extend the use of ‘last-resort’ antibiotics FirstWordPharma
December 14, 2021
Scientists have discovered a new potential treatment that has the ability to reverse antibiotic resistance in bacteria that cause conditions such as sepsis, pneumonia, and urinary tract infections.
CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections prnasia
October 19, 2021
Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453...
Report finds reducing primary care antibiotic use 'not enough' to halt antimicrobial resistance pharmatimes
August 06, 2021
A new report led by researchers at Imperial College London has found that reducing antibiotic prescribing in primary care may not be enough alone to halt the rise in drug resistant Escherichia coli (E. Coli) infections in England.
Study finds rise in antibiotic misuse in India during COVID first wave expresspharma
July 06, 2021
The researchers estimated that COVID-19 likely contributed to 216.4 million excess doses of antibiotics and 38 million more doses of azithromycin in adults from June 2020 through September 2020.
Sandoz outlines European antibiotic manufacturing expansion cphi-online
May 20, 2021
Novartis generics and biosimilars division will invest €150 million during the next 3-5 years at its Kundl, Austria and Palafolls, Spain sites while phasing out production of oral APIs at Les Franqueses site
Phico Therapeutics raises £7m to advance next-gen antibiotic candidate pharmatimes
May 12, 2021
Cambridge, UK-based biotech company Phico Therapeutics has announced new investments of £7m, led by the UK’s most active growth capital investor BGF.
First patient dosed with dalbavancin in S. aureus bacteremia trial europeanpharmaceuticalreview
April 29, 2021
The trial will assess the efficacy of a two week regimen of the FDA-approved antibiotic dalbavancin in treating 100 patients with Staphylococcus aureus bacteremia.
Sandoz to acquire GlaxoSmithKline’s cephalosporin antibiotics business pharmaceutical-business-review
February 20, 2021
Global leader in antibiotics and a division of Swiss multinational pharma company Novartis, Germany-based Sandoz has signed a contract to acquire GlaxoSmithKline’s (GSK) cephalosporin antibiotics.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page